Table 3.

Analysis of tumour MV in cancer patients.

Marker	% positive MV median [95% CI]	p-value
EMMPRIN
Healthy	27.70 [25.00–29.25]	8.215e-06
Non-healthy	26.45 [24.61–29.96]	0.003
Cancer	31.75 [30.70–32.35]	7.062e-08
head & neck cancer	30.65 [29.45–32.20]	1.589e-04
lung cancer	31.85 [30.95–33.95]	4.523e-07
breast cancer	31.70 [29.10– 32.90]	0.001
colorectal cancer	32.90 [29.30–34.20]	7.945e-04
EGFR
Healthy	2.20* [1.25–3.35]	0.065
Non-healthy	1.50* [0.55–4.15]	0.008
Cancer	3.20* [2.65–3.75]	0.002
head & neck cancer	3.15* [2.10–4.05]	0.002
lung cancer	2.95* [1.85–4.10]	0.080
breast cancer	3.50* [2.25–4.85]	0.037
colorectal cancer	3.25* [1.90–4.95]	0.005
EpCAM
Healthy	1.80* [1.20–2.65]	1.716e-06
Non-healthy	2.78* [1.60–4.15]	0.008
Cancer	3.60* [3.15–4.05]	2.079e-07
head & neck cancer	3.65* [3.00–4.30]	6.227e-07
lung cancer	3.20* [2.30–4.10]	0.006
breast cancer	3.80* [2.65–5.00]	5.860e-07
colorectal cancer	3.95* [2.50–5.35]	0.003
MUC1
Healthy	1.75* [1.30–2.40]	3.015e-06
Non-healthy	2.30* [1.91–3.83]	0.399
Cancer	2.90* [2.50–3.35]	9.920e-07
head & neck cancer	2.55* [2.05–3.35]	2.934e-05
lung cancer	3.51* [2.74–4.20]	3.020e-06
breast cancer	3.08* [2.15–4.50]	2.916e-04
colorectal cancer	2.10* [1.44–2.95]	0.004

Significance was calculated for healthy and non-healthy controls versus all cancer patients and for cancer patients and cancer subgroups versus all controls (healthy/non-healthy). Only for MUC1, significance for cancer subgroups was calculated versus healthy controls due to the reactive increase of MUC⁺ MV in non-healthy patients. *Indicates median calculation with [23].